Modeling highlights the challenge of maintaining HCV micro-elimination among people who inject drugs

Background & AimsPeople who inject drugs (PWID) are at high risk for acquiring and transmitting hepatitis C virus (HCV). Direct-acting antiviral (DAA) therapy leads to high cure rates. However, the lack of protective immunity after cure and high rates of reinfection in PWID necessitates access to multiple DAA treatments per PWID to reach the World Health Organization goal of HCV elimination, defined as 90% HCV incidence reduction. A major public health concern is that once the elimination goal is met, treatment of PWID will be stopped or significantly limited by a reduction in resources and complacency. MethodsWe refined and extended our agent-based model to study the effects of varying levels of DAA treatment among HCV-infected PWID from Chicago, IL and the effects of stopping or reducing DAAs treatment after elimination is reached. The model uses individual temporal viral load profiles to determine transmission probabilities relative to the HCV RNA titers of receptive syringe-sharing PWID. ResultsModeling predicts that insufficient annual DAA treatment ([≤]2.5%, 25 per 1000 PWID) risks increasing HCV incidence. Elimination can be achieved within 10 years with annual treatment of [≥]7.5%. When DAA treatment is stopped, the rate of new chronic HCV infections rapidly increases, exceeding the elimination goal within 12 months and returns to pre-elimination levels within 5 years. Annual treatment of [≥]0.5% would maintain the elimination goal. This equates to identifying and treating 160 infected people in a PWID population of 32,000 each year, which would be highly resource intensive. ConclusionThe challenge to maintain the elimination goal once met, underscores the importance of augmenting DAA treatment with interventions strategies such as syringe service programs and vaccines.